IMVT Immunovant, Inc.

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Our investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection. We have initiated Phase 2 studies in two target indications: myasthenia gravis (MG) and Gravesí ophthalmopathy (GO). We submitted an IND in one additional indication, warm autoimmune hemolytic anemia (WAIHA), in November 2019. We plan to continue expanding our pipeline with innovative therapies that could transform the lives of patients living with autoimmune diseases.

$13.08  -0.91 (-6.51%)
As of 03/04/2021 15:59:59 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Small cap
Health Care
Biotechnology
USA
USA
12/19/2019
97,971,243
2,143,341
$1,370,617,690
0.00%
SEC Edgar Online
10-Q
10-K
45258J102
US45258J1025
BJRFSB7

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
3.31
0.00
-24.10%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy